<?xml version='1.0' encoding='utf-8'?>
<document id="29368050"><sentence text="Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors."><entity charOffset="11-23" id="DDI-PubMed.29368050.s1.e0" text="posaconazole" /><entity charOffset="118-129" id="DDI-PubMed.29368050.s1.e1" text="idasanutlin" /><pair ddi="false" e1="DDI-PubMed.29368050.s1.e0" e2="DDI-PubMed.29368050.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29368050.s1.e0" e2="DDI-PubMed.29368050.s1.e1" /></sentence><sentence text="Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator"><entity charOffset="0-11" id="DDI-PubMed.29368050.s2.e0" text="Idasanutlin" /></sentence><sentence text=" To optimize its dosing conditions, a number of clinical pharmacology characteristics were examined in this multi-center trial in patients with advanced solid tumors" /><sentence text="" /><sentence text="This was an open-label, single-dose, crossover clinical pharmacology study investigating the effects of strong CYP3A4 inhibition with posaconazole (Part 1), two new oral formulations (Part 2), as well as high-energy/high-fat and low-energy/low-fat meals (Part 3) on the relative bioavailability of idasanutlin"><entity charOffset="134-146" id="DDI-PubMed.29368050.s5.e0" text="posaconazole" /><entity charOffset="298-309" id="DDI-PubMed.29368050.s5.e1" text="idasanutlin" /><pair ddi="false" e1="DDI-PubMed.29368050.s5.e0" e2="DDI-PubMed.29368050.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29368050.s5.e0" e2="DDI-PubMed.29368050.s5.e1" /></sentence><sentence text=" After completing Part 1, 2, or 3, patients could have participated in an optional treatment with idasanutlin"><entity charOffset="98-109" id="DDI-PubMed.29368050.s6.e0" text="idasanutlin" /></sentence><sentence text=" Clinical endpoints were pharmacokinetics (PK), pharmacodynamics (PD) of MIC-1 elevation (Part 1 only), and safety/tolerability" /><sentence text="" /><sentence text="The administration of posaconazole 400 mg BID × 7 days with idasanutlin 800 mg resulted in a slight decrease (7%) in Cmax and a modest increase (31%) in AUC for idasanutlin, a marked reduction in Cmax (~ 60%) and AUC0 (~ 50%) for M4 metabolite, and a minimal increase (~ 24%) in serum MIC-1 levels"><entity charOffset="22-34" id="DDI-PubMed.29368050.s9.e0" text="posaconazole" /></sentence><sentence text=" Cmax and AUC were both 45% higher for the SDP formulation" /><sentence text=" While the low-fat meal caused a less than 20% increase in all PK exposure parameters with the 90% CI values just outside the upper end of the equivalence criteria (80-125%), the high-fat meal reached bioequivalence with dosing under fasting" /><sentence text="" /><sentence text="In patients with solid tumors, multiple doses of posaconazole, a strong CYP3A4 inhibitor, minimally affected idasanutlin PK and PD without clinical significance"><entity charOffset="49-61" id="DDI-PubMed.29368050.s13.e0" text="posaconazole" /></sentence><sentence text=" The SDP formulation improved rBA/exposures by ~ 50% without major food effect" /><sentence text="" /></document>